奥希替尼治疗晚期非小细胞肺癌安全性的系统评价再评价
Safety of osimertinib for advanced non-small cell lung cancer with EGFR mutation: an overview of systematic reviews
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 | 〉 |